EXAS Company Profile and Key Details

Q: Who are the executives of EXAS?

James HerriottSenior Vice President, Gen. Counsel & Sec.Mr. Everett V. CunninghamChief Commercial OfficerMr. Tim CaprezChief Compliance Counsel & Vice PresidentMs. Megan JonesAssociate Mang. of Investor RelationsMr. Kevin T. ConroyChairman of The Board & Chief Executive OfficerMr. D. Scott CowardChief Legal OfficerMr. Graham P. LidgardEmeritus Chief Science OfficerMs. Sarah CondellaExecutive Vice President of HRMr. Vic ParkerHead of SalesDr. Jorge A. Garces Ph.D.Chief Science OfficerMr. Sri KalluriChief Information OfficerMr. James HerriottSenior Vice President, Gen. Counsel & Sec.Ms. Kristen WeilerVice President of MarketingMr. Jeffrey T. Elliott CFAExecutive Vice President & Chief Financial Officer

NASDAQ : EXAS

Exact Sciences

$104.91

At Close 4:00 PM

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Exact Sciences Corporation (EXAS) stock remained unchanged at $104.91 a share on NASDAQ. The stock opened at $104.91, fluctuating between $104.91 to $104.91 during the session.

Stock Snapshot

104.91

Prev. Close

20.03B

Market Cap

104.91

Day Low

-95.37272727272727

P/E Ratio

-1.1

EPS (TTM)

0.18

Cash Flow per Share

104.91

Open

190.89M

Number of Shares

104.91

Day High

99.02%

Free Float in %

17.37

Book Value

21.56M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 20, 2026	104.93	104.98	104.90	104.91	21.56M
Mar 19, 2026	103.78	103.96	103.72	103.92	1.88M
Mar 18, 2026	103.81	103.96	103.75	103.75	1.5M
Mar 17, 2026	103.70	104.00	103.68	103.94	1.45M
Mar 16, 2026	103.69	103.92	103.60	103.85	2.85M
Mar 13, 2026	103.53	103.69	103.45	103.57	2.5M
Mar 12, 2026	103.37	103.41	103.26	103.27	1.28M
Mar 11, 2026	103.40	103.50	103.31	103.40	1.37M
Mar 10, 2026	103.60	103.69	103.33	103.37	2.61M
Mar 09, 2026	103.42	103.75	103.22	103.71	3.18M
Mar 06, 2026	103.35	103.52	103.26	103.50	1.57M
Mar 03, 2026	103.21	103.46	103.10	103.37	2.8M
Mar 02, 2026	103.25	103.50	103.10	103.35	1.78M
Feb 27, 2026	103.27	103.39	102.95	103.38	2.67M
Feb 26, 2026	103.29	103.35	103.20	103.25	1.91M
Feb 25, 2026	103.45	103.45	103.20	103.27	2.24M
Feb 24, 2026	103.60	103.67	103.38	103.45	2.37M
Feb 23, 2026	103.50	103.65	103.37	103.39	1.53M
Feb 20, 2026	103.30	103.50	103.20	103.43	2.71M
Feb 19, 2026	103.40	103.41	103.21	103.29	1.93M

Contact Details

Madison, WI 53719

United States

https://www.exactsciences.com 608 284 5700

About Company

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Stock Peers

IDXX

17+3.21%

IDEXX Laboratories, Inc.$545.79 MEDP

5.4+1.30%

Medpace Holdings, Inc.$420.67 NTRA

6.18+3.32%

Natera, Inc.$192.54 ILMN

-1.03-0.72%

Illumina, Inc.$141.51 ICLR

-2.6-2.23%

ICON Public Limited Company$113.78 GH

0.74+0.78%

Guardant Health, Inc.$95.66 BLLN

3.49+4.22%

BillionToOne, Inc.$86.12 GRAL

1.06+1.78%

GRAIL, Inc.$60.71 RDNT

1.78+3.40%

RadNet, Inc.$54.17 TWST

0.62+1.26%

Twist Bioscience Corporation$49.79

Company Overview

The stock is currently trading near its 52-week high $38.81 and $104.98. With a market capitalization of about $20.03 billion, Exact Sciences Corporation is classified as a large-cap and shows higher-than-market volatility (beta ~1.44). Key stats such as the average daily volume over the past year has been around 2.53 million shares, trading with heavier-than-usual volume. Headquartered in Madison, WI, Exact Sciences Corporation operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Kevin T. Conroy, the company employs approximately 6,900 people and listed since February 01, 2001. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.19%, SMA50 0.83%, SMA200 46.46%). The stock’s 14-day RSI is 66.45 (firm momentum), while the ATR of 0.33 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.41% below its high and over 166.03% above its low.

Valuation Metrics

Exact Sciences Corporation trades at a P/E ratio of -95.72, slightly below the S&P 500 average, with a price-to-sales ratio of 6.17 and a price-to-book ratio of 8.29 trading at moderately above to book value. The P/FCF stands at 56.13, also below market averages.

Dividend & Fair Value

Exact Sciences Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $99.58. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Exact Sciences Corporation generated EPS of -$1.10 over the past year. Five-year average earnings growth is 27.36%. The latest quarter delivered EPS of -$0.45. The next quarter is forecast at -$0.19. Next year's EPS is expected at $22.99. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 8 Buy ratings, 9 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $105.00 to $46.00. The high target offers 0.09% upside. The low target suggests -56.15% downside. The mean target is $79.45. This offers -24.27% upside. Exact Sciences Corporation earnings surprise history is a mixed track record. The quarter that ended February 13, 2026, missed forecasts by 316.94%. The prior quarter beat by -179.64%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in November 05, 2024.

Shareholding & Insider Activity

Exact Sciences Corporation has 189.32 million shares outstanding. The public float is 187.46 million shares, elevated short interest at 4.15% of float. This equals 6.88 million shares. The short ratio is 3.0 days. Institutional investors hold 96.5% of the float. Insiders own 0.91%. Conroy Kevin T holds 1.07 million shares, Condella Sarah has 72.61 thousand shares and Zanotti Katherine S has 60.76 thousand shares. Over the past six months, insider transactions show net selling. They sold 6.00 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Exact Sciences generated $2.50B in revenue, or $13.88 per share. Gross margin was 73.83%, operating margin -8.60%, and net profit margin -8.17%. Returns are negative, with ROA at -3.15% and ROE at -6.49%.
On valuation metrics, Exact Sciences trades at a P/E of -95.72, P/S of 6.17 and P/B of 8.29. The current ratio is 2.23 and quick ratio is 1.97. Operationally, the company’s inventory turnover is 5.92 and cash conversion cycle is 29.99 days. Debt-to-equity is 1.05, supported by a cash flow-to-debt ratio of 0.19.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Exact Sciences posted revenue of $2.50B, down slightly from $2.08B in the prior quarter. Gross profit was $1.85B (margin 73.83%). Operating income was - $215.01M (margin -8.6%). Net income was- $204.15M (EPS - $1.13).
The company ended the quarter with $777.64M in cash and short-term investments, a total debt of $2.55B, and net debt of $1.95B. Total assets were $6.47B, with equity of $3.15B. Financials further reflected stability, with operating cash flow of $156.12M, free cash flow of $31.93M, and capital expenditures of - $124.19M.

Price Forecast & Outlook

Our AI price prediction model suggests that Exact Sciences Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.56%, with price expected at $105.50 by April 03, 2026, within a range of $105.04 to $105.97 3-Month Outlook: Projected fall of -41.22%, reaching $61.67 by June 18, 2026, with a range of $52.34 to $66.58. 1-Year Outlook: Projected gain of 5.34%, with price at $110.51 by March 19, 2027, within a range of $103.21 to $116.01.

Key Takeaways

Exact Sciences Corporation (NASDAQ:EXAS) shares are flat 0.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Exact Sciences Corporation trading at a premium to the broader market with a P/E of -95.72. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $87.17, suggesting -16.91% downside. Our AI forecast model points to short-term strength (0.56% over two weeks), a medium-term fall (-41.22% over three months), and a longer-term gain (5.34% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Exact Sciences Corporation (EXAS) stock price?

Exact Sciences Corporation (NASDAQ: EXAS) stock price is $104.91 in the last trading session. During the trading session, EXAS stock reached the peak price of $104.91 while $104.91 was the lowest point it dropped to. The percentage change in EXAS stock occurred in the recent session was 0% while the dollar amount for the price change in EXAS stock was $0.00.

EXAS's industry and sector of operation?

The NASDAQ listed EXAS is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Exact Sciences Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of EXAS?

James Herriott
Senior Vice President, Gen. Counsel & Sec.
Mr. Everett V. Cunningham
Chief Commercial Officer
Mr. Tim Caprez
Chief Compliance Counsel & Vice President
Ms. Megan Jones
Associate Mang. of Investor Relations
Mr. Kevin T. Conroy
Chairman of The Board & Chief Executive Officer
Mr. D. Scott Coward
Chief Legal Officer
Mr. Graham P. Lidgard
Emeritus Chief Science Officer
Ms. Sarah Condella
Executive Vice President of HR
Mr. Vic Parker
Head of Sales
Dr. Jorge A. Garces Ph.D.
Chief Science Officer
Mr. Sri Kalluri
Chief Information Officer
Mr. James Herriott
Senior Vice President, Gen. Counsel & Sec.
Ms. Kristen Weiler
Vice President of Marketing
Mr. Jeffrey T. Elliott CFA
Executive Vice President & Chief Financial Officer

How EXAS did perform over past 52-week?

EXAS's closing price is 170.32% higher than its 52-week low of $38.81 where as its distance from 52-week high of $104.98 is -0.07%.

How many employees does EXAS have?

Number of EXAS employees currently stands at 6,900.

Link for EXAS official website?

Official Website of EXAS is: https://www.exactsciences.com

How do I contact EXAS?

EXAS could be contacted at phone 608 284 5700 and can also be accessed through its website. EXAS operates from 5505 Endeavor Lane, Madison, WI 53719, United States.

How many shares of EXAS are traded daily?

EXAS stock volume for the day was 21.56M shares. The average number of EXAS shares traded daily for last 3 months was 2.53M.

What is the market cap of EXAS currently?

The market value of EXAS currently stands at $20.03B with its latest stock price at $104.91 and 190.89M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	6900
Beta	1.44
Sales or Revenue	$2.50B
5Y Sales Change%	2.731%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

EXAS Company Profile and Key Details

Exact Sciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Key Takeaways

Price Forecast & Outlook